Alkermes Plc (NASDAQ:ALKS) — Market Cap & Net Worth

$7.69 Billion USD · Rank #2709

Market Cap & Net Worth: Alkermes Plc (ALKS)

Alkermes Plc (NASDAQ:ALKS) has a market capitalization of $7.69 Billion ($7.69 Billion) as of September 15, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #2709 globally and #983 in its home market, demonstrating a -2.24% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alkermes Plc's stock price $45.83 by its total outstanding shares 167763272 (167.76 Million). Also see Alkermes Plc asset portfolio for a full breakdown of the balance sheet.

Alkermes Plc Market Cap History: 2015 to 2026

Alkermes Plc's market capitalization history from 2015 to 2026. Data shows change from $13.32 Billion to $7.69 Billion (-2.79% CAGR). Also see cash flow conversion of Alkermes Plc for how efficiently the company converts equity into cash flow.

Index Memberships

Alkermes Plc is a constituent of 7 market indices:

Index	Total Market Cap	Weight (%)	Rank by Market Cap
ARCA Biotechnology BTK	$1.06 Trillion	0.73%	#23 of 30
Dow Jones Biotechnology DJUSBT	$1.16 Trillion	0.66%	#17 of 39
ARCA Pharmaceutical DRG	$3.40 Trillion	0.23%	#17 of 24
NASDAQ Health Care IXHC	$2.68 Trillion	0.29%	#67 of 976
NASDAQ Composite IXIC	$41.94 Trillion	0.02%	#312 of 3165
NASDAQ Biotechnology NBI	$1.89 Trillion	0.41%	#47 of 263
S&P Small-Cap 600 Index SML	$1.62 Trillion	0.38%	#30 of 602

Weight: Alkermes Plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Alkermes Plc Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Alkermes Plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Alkermes Plc share price for real-time trading data and today's change.

Latest Price to Sales (P/S) Ratio

3.18x

Alkermes Plc's market cap is 3.18 times its annual revenue

Industry average: 0.58x Higher than industry average

Latest Price to Earnings (P/E) Ratio

19.42x

Alkermes Plc's market cap is 19.42 times its annual earnings

Industry average: 2.05x Higher than industry average

What These Ratios Tell Investors:

Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
Industry comparison provides context for whether the company is valued higher or lower than peers.

Year	Market Cap (USD)	Revenue (USD)	Net Income (USD)	P/S Ratio	P/E Ratio
2016	$9.32 Billion	$745.69 Million	-$208.44 Million	12.50x	N/A
2017	$9.18 Billion	$903.37 Million	-$157.94 Million	10.16x	N/A
2018	$4.95 Billion	$1.09 Billion	-$139.31 Million	4.52x	N/A
2019	$3.42 Billion	$1.17 Billion	-$196.62 Million	2.92x	N/A
2020	$3.35 Billion	$1.04 Billion	-$110.86 Million	3.22x	N/A
2021	$3.90 Billion	$1.17 Billion	-$48.17 Million	3.32x	N/A
2022	$4.38 Billion	$1.11 Billion	-$158.27 Million	3.94x	N/A
2023	$4.65 Billion	$1.66 Billion	$355.76 Million	2.80x	13.08x
2024	$4.82 Billion	$1.56 Billion	$367.07 Million	3.10x	13.14x
2025	$4.69 Billion	$1.48 Billion	$241.66 Million	3.18x	19.42x

Competitor Companies of ALKS by Market Capitalization

Companies near Alkermes Plc in the global market cap rankings as of September 15, 2026. Review how tangible is Alkermes Plc's equity to assess the quality of the company's equity after excluding intangible assets.

Key companies related to Alkermes Plc by market ranking:

Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
GALDERMA GROUP AG (NYSE:GALDY): Ranked #627 globally with a market cap of $44.32 Billion USD.
Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #639 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
Haleon plc (NYSE:HLN): Ranked #662 globally with a market cap of $41.35 Billion USD.

Market capitalization comparison (in billions USD)

Rank	Company	Symbol	Market Cap	Price
#518	Takeda Pharmaceutical Co Ltd ADR	NYSE:TAK	$52.60 Billion	$16.65
#627	GALDERMA GROUP AG	NYSE:GALDY	$44.32 Billion	$38.01
#639	Takeda Pharmaceutical Company Limited	F:TKDA	$43.60 Billion	€15.60
#662	Haleon plc	NYSE:HLN	$41.35 Billion	$9.39

Alkermes Plc Historical Marketcap From 2015 to 2026

Between 2015 and today, Alkermes Plc's market cap moved from $13.32 Billion to $ 7.69 Billion, with a yearly change of -2.79%.

Year	Market Cap	Change (%)
2026	$7.69 Billion	+63.80%
2025	$4.69 Billion	-2.71%
2024	$4.82 Billion	+3.68%
2023	$4.65 Billion	+6.16%
2022	$4.38 Billion	+12.34%
2021	$3.90 Billion	+16.59%
2020	$3.35 Billion	-2.21%
2019	$3.42 Billion	-30.87%
2018	$4.95 Billion	-46.08%
2017	$9.18 Billion	-1.53%
2016	$9.32 Billion	-29.98%
2015	$13.32 Billion	--

End of Day Market Cap According to Different Sources

On Sep 15th, 2026 the market cap of Alkermes Plc was reported to be:

Source	Market Cap
Yahoo Finance	$7.69 Billion USD
MoneyControl	$7.69 Billion USD
MarketWatch	$7.69 Billion USD
marketcap.company	$7.69 Billion USD
Reuters	$7.69 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Alkermes Plc

NASDAQ:ALKS USA Drug Manufacturers - Specialty & Generic

Market Cap

$7.69 Billion

Market Cap Rank

#2709 Global

#983 in USA

Share Price

$45.83

Change (1 day)

-0.30%

52-Week Range

$27.13 - $55.22

All Time High

$80.14